香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 自願性公告 依蘇帕格魯肽α的新獸藥臨床試驗申請獲受理 本公告乃由廣州銀諾醫藥集團股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，以向本公司股東（「股東」）及有意投資者提供有關本公司業務最 新進展的資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於2026年2月4日，本公司核心產 品依蘇帕格魯肽α用於治療寵物糖尿病的新獸藥臨床試驗申請已獲中華人民共和 國農業農村部（「農業部」）正式受理。預計將於2026年第一季度開始I期臨床試驗。 董事會認為，研發寵物糖尿病藥物具有廣闊的前景。由於人們愈發願意接受並花 費金錢延長寵物的壽命，董事會認為，此類研發符合本集團的長期業務發展策 略，並將為本集團未來 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02591 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | ...

Core Insights - The J.P. Morgan Healthcare Conference highlighted the weight loss market as a key focus, with major pharmaceutical companies like Eli Lilly, Novo Nordisk, and Pfizer emphasizing their commitment to this sector [1] - Pfizer plans to launch weight loss assets acquired from Metzera by mid-2028, indicating a long-term strategy in the weight loss market [1] - Eli Lilly's Orforglipron has been submitted for approval in China, following its inclusion in the FDA's expedited approval list in November 2025 [1] Pricing Strategies - Novo Nordisk announced a significantly lower price for its oral version of semaglutide (Wegovy) compared to its injectable counterpart, with monthly costs starting at approximately $149 for self-paying patients [2] - The price of injectable semaglutide (Ozempic) was previously set at $969 per month, while Wegovy was priced at $1,349 per month [2] - Agreements with the U.S. government will lead to price reductions for semaglutide and Orforglipron starting in 2026, with some products capped at $50 per month [3] Market Competition - The GLP-1 market is experiencing intense competition, with 88 small molecule GLP-1 drugs currently in development, including six in Phase III trials [3] - A price war has erupted in the GLP-1 injection market, driven by increased supply and the expiration of patents for key products [4] - The introduction of new competitors and the expansion of indications for GLP-1 drugs are reshaping the market landscape [5] Domestic Market Dynamics - The new national medical insurance directory in China has initiated a price competition era for GLP-1 products, with significant discounts being offered on e-commerce platforms [4][6] - The price of semaglutide and other competing products has seen drastic reductions, with some prices dropping to as low as 20% of their original costs [5][6] - The entry of multiple domestic companies into the GLP-1 market is intensifying the price competition, particularly as patents expire [9][19] Future Outlook - The GLP-1 market is expected to grow significantly, with projections indicating a potential market size exceeding $100 billion by 2030 [16] - The competition is shifting from price-based to innovation-based, focusing on multi-target therapies and expanded indications [16] - The expiration of key patents is likely to lead to an influx of generic competitors, further intensifying the price competition [17][19]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州銀諾醫藥集團股份有限公司（於中華人民共和國成立的股份有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02591 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 2. 股份分類 ...

Core Viewpoint - The "Annual Excellence Innovation IPO" award was presented to Silver诺医药-B (02591.HK) during the "Technology Empowerment · Capital Breakthrough" online sharing session held by 格隆汇 on December 22, recognizing the company's achievements in product, model, and organizational innovation over the past year [1] Group 1 - The award aims to honor newly listed companies that have achieved excellent results through continuous innovation in response to market trends [1]

Core Viewpoint - The "Annual Excellence in Innovation IPO" award recognizes companies that have demonstrated significant achievements in product, model, and organizational innovation over the past year, highlighting their ability to keep pace with market trends through continuous innovation [4]. Group 1: Award Recipients - Six companies were awarded the "Annual Excellence in Innovation IPO" award: MIRXES-B (02629.HK), Wuyi Vision (06651.HK), Yino Pharma (02591.HK), Yunhan Chip City (301563.SZ), Yunjing (02670.HK), and Yunzhisheng (09678.HK) [1]. - The ranking of the awarded companies is not in any specific order and is based on the first letter of their names [1]. Group 2: Evaluation Criteria - The evaluation for the award was based on quantitative data analysis and assessments from an expert review panel [4]. - The award aims to create a valuable reference list of listed companies and unicorns within the investment community, covering all companies listed on major exchanges including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4].

Core Viewpoint - The "Golden Award" annual excellence company selection by Gelonghui recognizes innovative companies in the IPO sector, highlighting their achievements in product, model, and organizational innovation over the past year [1][2]. Group 1: Award Winners - Six companies received the "Annual Excellence Innovation IPO" award: MIRXES-B (02629.HK), Wuyi Vision (06651.HK), Yinnuo Pharmaceutical-B (02591.HK), Yunhan Chip City (301563.SZ), Yunjin (02670.HK), and Yunzhisheng (09678.HK) [1]. - The ranking of the award winners is not in any particular order and is based on the first letter of the company names [1]. Group 2: Evaluation Criteria - The award evaluates companies based on quantitative data analysis and expert review, focusing on their innovation in products, business models, and organizational structures [1]. - The aim of the selection is to recognize new listed companies that have achieved excellent results through continuous innovation and alignment with market trends [1]. Group 3: Scope of the Selection - The "Golden Award" selection covers all listed companies and unicorns on major stock exchanges, including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [2]. - The initiative is driven by the vision of providing valuable references for investors regarding listed companies and unicorns in the market [2].

廣州銀諾醫藥集團股份有限公司 章程 （H股發行後適用） 1 | 第一章 | 總則 | 4 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 5 | | 第三章 | 股份 | 6 | | 第一節 | 股份發行 | 6 | | 第二節 | 股份增減和回購 | 10 | | 第三節 | 股份轉讓 | 11 | | 第四章 | 股東和股東會 | 12 | | 第一節 | 股東 | 12 | | 第二節 | 股東會的一般規定 | 18 | | 第三節 | 股東會的召集 | 21 | | 第四節 | 股東會的提案與通知 | 23 | | 第五節 | 股東會的召開 | 25 | | 第六節 | 股東會的表決和決議 | 29 | | 第五章 | 董事會 | 34 | | 第一節 | 董事 | 34 | | 第二節 | 董事會 | 38 | | 第六章 | 總經理及其他高級管理人員 | 43 | | 第七章 | 監事會 | 45 | | --- | --- | --- | | 第一節 | 監事 | 45 | | 第二節 | 監事會 | 45 | | 第八章 | 財務會計制度、利潤分配和審計 | 4 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 章程修訂 本公告乃廣州銀諾醫藥集團股份有限公司（「本公司」）根據香港聯合交易所有限公 司（「聯交所」）證券上市規則第13.51(1)條刊發。 H股於2025年8月15日在聯交所主板完成發行上市（「上市」）後，為反映本公司上 市後註冊資本、股份總數等情況的相關變動，本公司須修訂其章程（「章程」）並辦 理完成有關章程變更的備案。 於本公告日期，董事會包括執行董事WANG QINGHUA博士、姜帆女士、徐文潔 女士及黃冰先生；非執行董事HO KYUNG SHIK先生及衡磊先生；及獨立非執行 董事陶武平先生、宋瑞霖博士及陳向榮先生。 根據本公司於2024年10月30日的臨時股東會會議通過的決議案，董事會及董事 會授權人員已獲 ...

Core Viewpoint - The stock of Innovent Biologics-B (02591) rose over 3%, reaching HKD 32, following the announcement that its innovative drug, Icosapent Ethyl (brand name: Yinuo Qing®), has been included in the 2025 National Medical Insurance Drug List in China, marking a significant step towards making diabetes treatment more accessible [1]. Group 1: Company Developments - Innovent Biologics' Icosapent Ethyl is the first long-acting human GLP-1 receptor agonist (GLP-1RA) developed in China, aimed at controlling blood sugar levels in adult patients with type 2 diabetes [1]. - The drug will officially be implemented in the national insurance scheme starting January 1, 2026, enhancing its market accessibility [1]. Group 2: Industry Impact - The inclusion of Icosapent Ethyl in the national insurance list aligns with the "Healthy China 2030" initiative, which aims to advance diabetes prevention and treatment [1]. - The National Guidelines for Diabetes Prevention and Management (2025) classify Icosapent Ethyl as a GLP-1RA injectable medication, providing a policy framework for its use in primary healthcare settings [1]. - The guidelines highlight GLP-1RA as a crucial treatment option for adult type 2 diabetes patients with comorbidities such as atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and those needing weight management [1].